Document Detail


Induction therapy in acute myeloid leukemia: intensifying and targeting the approach.
MedLine Citation:
PMID:  20087177     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE OF REVIEW: Acute myeloid leukemia (AML) is a heterogeneous group of clonal disorders which is treated with similar regimens despite the heterogeneity. The treatment approach for many years has used combination chemotherapy, with usually an anthracycline and cytarabine as the foundation. In the present review we will present new data from recently completed trials that have demonstrated advances in the treatment of AML. RECENT FINDINGS: We will discuss the recent trials that support the importance of dose intensification in younger patients either through increasing dose of the anthracycline, adding other agents such as gemtuzumab ozogamicin, or through 'timed sequential' therapy. We will promote the importance of treating the older AML patient (>60 years old) and the various ways different groups are addressing a different biologically behaving disease and the patient being treated. These methods include dose reduction, dose intensification and new agents with a better toxicity profile. SUMMARY: Due to aggressive induction therapy, patients with AML are having better remission and survival outcomes. New agents that are targeted to specific molecular abnormalities in the AML cell are being studied as additions to induction therapy.
Authors:
Hugo F Fernandez; Jacob M Rowe
Related Documents :
10520027 - Real-time rt-pcr for the detection and quantification of aml1/mtg8 fusion transcripts i...
28827 - Recent developments in the supportive therapy of acute myelogenous leukemia.
22172907 - Randomized clinical trial to assess the efficacy of radiotherapy in primary mediastinal...
16454127 - Significance of cytogenetic abnormalities in acute myeloid leukaemia.
16382127 - Radiotherapy as primary treatment for stage ie and iie nasal natural killer/t-cell lymp...
23313257 - Risk factors of peritoneal recurrence in eso-gastric signet ring cell adenocarcinoma: r...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current opinion in hematology     Volume:  17     ISSN:  1531-7048     ISO Abbreviation:  Curr. Opin. Hematol.     Publication Date:  2010 Mar 
Date Detail:
Created Date:  2010-02-10     Completed Date:  2010-04-27     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9430802     Medline TA:  Curr Opin Hematol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  79-84     Citation Subset:  IM    
Affiliation:
Department of Blood and Marrow Transplantation, Moffitt Cancer Center and Research Institute, Tampa, Florida, USA. hugo.fernandez@moffitt.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aminoglycosides / therapeutic use*
Anthracyclines / therapeutic use*
Antibodies, Monoclonal / therapeutic use*
Antineoplastic Agents / therapeutic use
Antineoplastic Combined Chemotherapy Protocols
Dose-Response Relationship, Drug
Drug Administration Schedule
Drug Delivery Systems
Humans
Leukemia, Myeloid, Acute / drug therapy*
Chemical
Reg. No./Substance:
0/Aminoglycosides; 0/Anthracyclines; 0/Antibodies, Monoclonal; 0/Antineoplastic Agents; 0/gemtuzumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  JAK2 kinase inhibitors and myeloproliferative disorders.
Next Document:  Nontuberculous mycobacterial lung disease.